RHJA
AEGR

Rice Hall James & Associates’s Aegerion Pharmaceuticals AEGR Stock Holding History

Rice Hall James & Associates’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-78,804
Closed -$1.07M – 331
2015
Q3 		$1.07M Buy
78,804
+5,583
+8% +$99.4K 0.07% 231
2015
Q2 		$1.39M Sell
73,221
-86,829
-54% -$1.88M 0.08% 233
2015
Q1 		$4.19M Buy
160,050
+20,451
+15% +$520K 0.24% 104
2014
Q4 		$2.92M Buy
139,599
+52,973
+61% +$1.33M 0.18% 153
2014
Q3 		$2.89M Buy
86,626
+29,557
+52% +$917K 0.2% 128
2014
Q2 		$1.83M Buy
57,069
+39,011
+216% +$1.45M 0.12% 198
2014
Q1 		$834K Buy
+18,058
New +$1.06M 0.06% 234

Other funds holding AEGR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Rice Hall James & Associates's AEGR Position: Q4 2015 in Review

Rice Hall James & Associates sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2015, closing a stake of 78,804 shares — an estimated $1.07M sold.

Rice Hall James & Associates first reported a position in AEGR in Q1 2014 and held it in 7 quarters. The position peaked at $4.19M in Q1 2015. 109 funds tracked by Wall St. Rank hold AEGR as of Q4 2015.

  • Rice Hall James & Associates reported no remaining Aegerion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Rice Hall James & Associates sold 78,804 Aegerion Pharmaceuticals shares in Q4 2015, an estimated $1.07M.
  • Rice Hall James & Associates first reported a position in Aegerion Pharmaceuticals in Q1 2014 and held it in 7 quarters.
  • Rice Hall James & Associates's Aegerion Pharmaceuticals position peaked at $4.19M in Q1 2015.
  • 109 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2015.

Based on Rice Hall James & Associates's 13F filing for Q4 2015, filed 28 Jan 2016.